毕得医药: 关于使用自有资金支付募投项目所需资金并以募集资金等额置换的公告

Core Viewpoint - The company has announced the use of its own funds to pay for investment projects and will subsequently replace these with raised funds, ensuring efficient fund utilization and project implementation [1][5][6]. Fundraising Basic Information - The company raised a total of 1,622.91 million shares at a par value of 1.00 RMB per share, with net proceeds amounting to approximately 1,308.99 million RMB after deducting issuance costs [1][2]. - The total expected investment for the projects is 434.36 million RMB, with all raised funds allocated to these projects [2]. Reasons for Using Own Funds - The company’s U.S. subsidiary, Bepharm Scientific Inc., initially used its own funds for project payments due to delays in foreign investment registration, with plans to replace these funds with raised capital later [3][5]. - Payments for salaries, bonuses, and other employee-related expenses must be made from the company's basic deposit accounts, not from the raised funds account, to comply with banking regulations [4][5]. - The need for frequent payments for project-related expenses makes it impractical to use the raised funds account directly, as it would complicate fund management and slow down project execution [4][5]. Operational Process for Fund Replacement - The company will submit payment requests for project-related expenses paid with its own funds, and within six months, will transfer equivalent amounts from the raised funds account to its basic deposit accounts [5][6]. Impact on Daily Operations - The decision to use own funds for project payments and later replace them with raised funds is expected to enhance fund utilization efficiency and ensure smooth project progress without affecting the normal implementation of investment projects [5][6]. Review Procedures - The board of directors approved the use of own funds for project payments, and this decision does not require shareholder meeting approval, ensuring compliance with relevant regulations [6][7].